• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by ICON plc

    5/26/26 4:13:26 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ICLR alert in real time by email
    6-K 1 iconearningscallanddeficie.htm 6-K Document


     
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
    FORM 6-K
     

    REPORT OF FOREIGN PRIVATE ISSUER
    PURSUANT TO RULE 13a-16 OR 15d-16
    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2026

    Commission File Number: 333-08704
     
    ICON plc
    (Translation of registrant's name into English)
    South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Ireland
    (Address of principal executive office)
     
    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F ☒   Form 40-F ☐



     




    As previously disclosed in the Form 12b-25 filed on May 1, 2026 by ICON plc (the “Company”) with the U.S. Securities and Exchange Commission (the “SEC”), the Company requires additional time to review and finalize the information required to be presented in its Annual Report on Form 20-F for the year ended December 31, 2025 (“Form 20-F”).
    On May 19, 2026, in accordance with standard procedures related to the delayed filing of the Form 20-F with the SEC, the Company received a written notice (“Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the periodic filing requirements for continued listing set forth in Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”). Nasdaq has provided the Company with 60 calendar days from the date of the notice to submit a plan to regain compliance.
    The Notice has no immediate effect on the listing or trading of the Company’s securities. However, if the Company fails to timely regain compliance with the Listing Rule, the Company’s securities will be subject to delisting from Nasdaq. The Company expects to regain compliance upon filing the Form 20-F, which it currently anticipates completing in advance of the conference call.
    On May 26, 2026, the Company issued a press release announcing that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026 and also receipt of the Notice. A copy of the press release is attached hereto as Exhibit 99.1.
    Exhibit List

    Exhibit
    Description
    99.1
    ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq

    Other Information

    Certain statements contained herein are forward-looking statements. All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding the finalization of and timing of filing the Form 20-F and the Company’s ability to regain compliance with the Listing Rule. You can identify many forward-looking statements by words such as “aims,” “anticipates,” “believes,” “continues,” “could,” “estimates,” “expects,” “focused,” “guidance,” “intends,” “may,” “opportunities,” “plans,” “position,” “potential,” “predicts,” “projects,” “proposed,” “seeks,” “should,” “will,” “would” and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. These statements are based on management's current expectations and information currently available. Actual results may differ materially from those stated or implied by forward-looking statements due to risks and uncertainties associated with the Company's management and operations, and forward-looking statements are not guarantees of future performance. Such risks and uncertainties include, but are not limited to: risks related to the ability of the Company to finalize the Form 20-F and complete the external audit; delays due to unforeseen additional work needed to complete the filing of the Form 20-F; risks related to Company’s plan to regain compliance with the Listing Rule; and other factors, including those factors described in the section entitled “Risk Factors” of the Company’s Annual Report on Form 20-F most recently filed with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made and the Company does not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise, except to the extent required by law.





    SIGNATURE
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
     
    ICON plc
    Date: May 26, 2026By:/s/ Nigel Clerkin
    Name:Nigel Clerkin
    Title:Chief Financial Officer



    Get the next $ICLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICLR

    DatePrice TargetRatingAnalyst
    5/18/2026$123.00Sector Perform
    RBC Capital Mkts
    3/26/2026$130.00Market Perform → Outperform
    BMO Capital Markets
    2/23/2026$135.00Hold → Buy
    Jefferies
    2/18/2026$120.00Hold → Buy
    TD Cowen
    2/17/2026$100.00Buy → Neutral
    Rothschild & Co Redburn
    2/12/2026$105.00Outperform → Market Perform
    Leerink Partners
    2/12/2026$75.00Neutral → Underperform
    BofA Securities
    1/8/2026$222.00Buy → Hold
    Truist
    More analyst ratings

    $ICLR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Murphy Ronan Martin

    4 - ICON PLC (0001060955) (Issuer)

    5/15/26 8:39:02 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Climax John Dr

    4 - ICON PLC (0001060955) (Issuer)

    5/15/26 8:38:31 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 4 filed by Director Mccague Eugene Pacelli

    4 - ICON PLC (0001060955) (Issuer)

    5/15/26 8:38:09 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026. The Company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 28, 2026 at 8:00am ET. The Company also announced that, as expected, as a consequence of not yet having filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the "Form 20-F"), the Company has received a written notice from Nasdaq indicating that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), w

    5/26/26 4:05:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON expands US early phase research capabilities with new clinic and outpatient centres

    New, 69.5K square-foot, state-of-the-art clinic in Texas integrates clinical, laboratory, and pharmacy infrastructure all under one roof Two new satellite outpatient clinics in Texas and Kansas will further expand recruitment reach and reduce visit burden ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced the expansion of its early phase capabilities with the opening of a new, state-of-the-art Clinical Research Unit (CRU) in San Antonio, Texas, as well as new satellite outpatient clinics in Houston, Texas and Lawrence, Kansas. These new, purpose-built clinics will significantly expand ICON's capacity to conduct first-in-human, healthy participant,

    5/13/26 8:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    HealthVerity to Acquire Symphony Health, Uniting Clinical Data and Commercial Analytics to Accelerate Breakthroughs Across the Healthcare Ecosystem

    Philadelphia, PA, May 05, 2026 (GLOBE NEWSWIRE) -- HealthVerity, Inc., the leader in privacy-protected real-world data exchange and patient identity solutions, today announced that it has entered into a definitive agreement to acquire Symphony Health Solutions Corporation, a commercial healthcare data business formerly part of ICON plc (NASDAQ:ICLR). The transaction is subject to customary closing conditions and is expected to close in May 2026. The transaction will define the next era of healthcare real-world data by bringing together HealthVerity's clinical data depth and experience with Symphony Health's commercial insights and scale into a single, connected view of the patient and

    5/5/26 8:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    SEC Filings

    View All

    SEC Form 6-K filed by ICON plc

    6-K - ICON PLC (0001060955) (Filer)

    5/27/26 4:41:05 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Amendment: SEC Form 6-K/A filed by ICON plc

    6-K/A - ICON PLC (0001060955) (Filer)

    5/27/26 4:29:30 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 20-F filed by ICON plc

    20-F - ICON PLC (0001060955) (Filer)

    5/27/26 4:24:40 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts resumed coverage on ICON plc with a new price target

    RBC Capital Mkts resumed coverage of ICON plc with a rating of Sector Perform and set a new price target of $123.00

    5/18/26 8:34:11 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc upgraded by BMO Capital Markets with a new price target

    BMO Capital Markets upgraded ICON plc from Market Perform to Outperform and set a new price target of $130.00

    3/26/26 8:38:54 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc upgraded by Jefferies with a new price target

    Jefferies upgraded ICON plc from Hold to Buy and set a new price target of $135.00

    2/23/26 8:29:27 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Leadership Updates

    Live Leadership Updates

    View All

    ICON Announces CEO Transition

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON's Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will continue to serve on the Board as a non-executive director to facilitate a smooth transition. Mr. Balfe has deep knowledge of the CRO industry and has served as ICON's Chief Operating Officer since January 2025. Prior to his appointment as Chief Operating Officer, Mr. Balfe was appointed to the

    9/4/25 8:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON Announces Results of Annual General Meeting

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website. Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions: RESOLUTION NUMBER RESOLUTION     TOTAL NUMBER OF VOTES     VOTE FOR     VOTE AGAINST     VOTE WITHHELD                   1.1

    7/23/25 4:20:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Anne Whitaker Appointed as Non-Executive Director

    MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

    4/3/25 6:13:56 PM ET
    $ICLR
    $TLX
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ICLR
    Financials

    Live finance-specific insights

    View All

    ICON Schedules Fourth Quarter and Full Year 2025 Earnings Conference Call and Acknowledges Receipt of Deficiency Notice from Nasdaq

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organization, today announced that it will release financial results for the fourth quarter and full year 2025 results after the market closes on Wednesday, May 27, 2026. The Company will hold a conference call and webcast to discuss its financial results and performance on Thursday, May 28, 2026 at 8:00am ET. The Company also announced that, as expected, as a consequence of not yet having filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the "Form 20-F"), the Company has received a written notice from Nasdaq indicating that it is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), w

    5/26/26 4:05:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON Reports Third Quarter 2025 Results

    Highlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter was $2.4 million or $0.03 per diluted share. Quarter three adjusted EBITDA was $396.7 million or 19.4% of revenue, representing an increase of 0.2% on quarter two 2025. Quarter three adjusted net income was $258.8 million or $3.31 per diluted ordinary share. Gross business wins in the quarter of $2,986 million, representing an increase of 0.7% on quarter two 2025. Net business wins in the quarter of $2,086 million, representing an increase of 1.4% on quarter two 2025; a net book to bill in the quarter of 1.02. Net debt was $2.9 bil

    10/22/25 4:25:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc Schedules Third Quarter 2025 Earnings Conference Call

    ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, October 22, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 23, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical research organisation. From molecule

    9/24/25 9:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ICON plc

    SC 13G/A - ICON PLC (0001060955) (Subject)

    11/12/24 11:54:03 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by ICON plc (Amendment)

    SC 13G/A - ICON PLC (0001060955) (Subject)

    2/9/24 11:49:03 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by ICON plc (Amendment)

    SC 13G/A - ICON PLC (0001060955) (Subject)

    1/30/24 12:11:57 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care